Eton Pharmaceuticals, Inc. (ETON)

From the record

Eton Pharmaceuticals, Inc.'s filings since 2017 show 3 warning events of 2 kinds: an auditor change (8-K item 4.01, 2 times, the latest 2025-06-20); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-11-16) (its current reports).

From the record

Eton Pharmaceuticals, Inc.'s 7 filed years say what it did: revenue went from $959 thousand in fiscal 2019 to $80 million in fiscal 2025, up 109% a year; it rose in 4 of 6 years; the deepest fall was 96% from fiscal 2019 to fiscal 2020; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Eton Pharmaceuticals, Inc.'s diluted share count grew about 2.3% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 27 sales and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Eton Pharmaceuticals, Inc. lost about 18 cents for every dollar of shareholders' money, and gross profitability: its products earned about 46 cents per dollar of everything the company owns. Leverage: it owed about 72 cents per dollar of assets, and net share issuance: its share count grew 3.9% over the year (the filed statements).

From the record

Eton Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $80 million in fiscal 2025 ranks in the top 37% by size; a net margin of -5.8% ranks in the top 28%; revenue growth of 55.5% a year over the last 3 filed years ranks in the top 23% (its annual reports).

From the record

Eton Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Brynjelsen, Sean (President & CEO, as filed), filing under that title since 2018-11-13, 8 years (top 23% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 38%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Eton Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $26 million against debt of $22 million leaves 4.5% of its assets as net cash, bottom 19% of its family; cash from operations less capital spending is 12.7% of revenue (top 19%); a gross margin of 53.5% (bottom 29%); research spending of 9.7% of revenue (bottom 15%) (its annual report).

From the record

Eton Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 55.5% a year over the last three filed years against 109% over all 7, slowing (bottom 12% of its family); the newest year grew 105% (top 17%); research spending grew 24.8% a year (top 19%); capital spending grew 106.1% a year (top 9%) (its annual reports). Eton Pharmaceuticals, Inc. reported 2 product lines in fiscal 2025: Product Sales and Royalties at $77 million (96%), License at $3 million (4%); 2 of 2 grew against the year before (its annual report).

From the record

Eton Pharmaceuticals, Inc.'s newest year against its own record: revenue of $80 million in fiscal 2025 came in 51.3% above the $53 million its prior three years' pace pointed to (top 19% of its family); net income of $5 million against a prior three-year average of $5 million (bottom 42%); a net margin of -5.8% against -18.4% before (top 48%) (its annual reports).